NCT01064648 2026-03-18
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
63 trialsNCT02535312 2026-03-18
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05098132 2026-03-18
SYNERGY-101
Synthekine
Phase 1/2 Recruiting
NCT06694454 2026-03-18
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Not yet recruiting
NCT04083599 2026-03-16
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT04165070 2026-03-16
MK-3475-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07472647 2026-03-16
SYS6090 Combination Therapy in Advanced Lung Cancer
Shanghai JMT-Bio Inc.
Phase 1/2 Not yet recruiting
NCT06173505 2026-03-13
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Xencor, Inc.
Phase 1/2 Terminated
NCT05636267 2026-03-09
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
Akeso
Phase 1/2 Terminated
NCT06162221 2026-03-09
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT07020221 2026-03-09
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Phase 1/2 Recruiting
NCT06772623 2026-02-27
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
AbbVie
Phase 1/2 Recruiting
NCT06996782 2026-02-24
ALTAIR
AstraZeneca
Phase 1/2 Recruiting
NCT05789082 2026-02-20
KRAScendo 170
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT03559049 2026-02-12
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT07397338 2026-02-09
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT06405230 2026-02-03
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
GlaxoSmithKline
Phase 1/2 Recruiting
NCT03337698 2025-12-12
Morpheus Lung
Hoffmann-La Roche
Phase 1/2 Completed
NCT05664971 2025-12-02
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Completed
NCT05469178 2025-10-29
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
BerGenBio ASA
Phase 1/2 Terminated
NCT04956640 2025-09-25
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
Phase 1/2 Recruiting
NCT07070440 2025-08-29
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
Dizal Pharmaceuticals
Phase 1/2 Recruiting
NCT03970746 2025-05-29
Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC
PDC*line Pharma SAS
Phase 1/2 Active not recruiting
NCT05431270 2025-01-31
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
Phase 1/2 Recruiting
NCT05501665 2024-10-17
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Recruiting
NCT03267316 2024-08-22
CANFOUR
Cantargia AB
Phase 1/2 Completed
NCT03319537 2024-05-23
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
NCT04647344 2024-04-25
A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Akeso
Phase 1/2 Completed
NCT03317496 2023-08-29
Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies
Pfizer
Phase 1/2 Terminated
NCT03840915 2023-08-21
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
EMD Serono
Phase 1/2 Completed
NCT01126736 2023-06-22
Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer
Eisai Inc.
Phase 1/2 Completed
NCT02983045 2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2 Completed
NCT03138889 2023-03-10
PROPEL
Nektar Therapeutics
Phase 1/2 Terminated
NCT02039674 2022-11-08
MK-3475-021
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT03085914 2022-09-23
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Incyte Corporation
Phase 1/2 Completed
NCT02347917 2022-04-12
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
Sumitomo Pharma Co., Ltd.
Phase 1/2 Completed
NCT04430933 2021-08-18
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
NextCure, Inc.
Phase 1/2 Withdrawn
NCT00700336 2021-07-20
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
CanBas Co. Ltd.
Phase 1/2 Completed
NCT02574078 2021-05-06
CheckMate370
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00794417 2020-12-10
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
Regeneron Pharmaceuticals
Phase 1/2 Terminated
NCT03706287 2020-04-06
Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC
Sichuan Cancer Hospital and Research Institute
Phase 1/2 Unknown
NCT00923273 2019-11-26
Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00389805 2018-10-31
Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
University of California, Davis
Phase 1/2 Completed
NCT00470548 2018-01-10
Abraxane and Alimta in Advanced Solid Tumors
University of California, Davis
Phase 1/2 Terminated
NCT03201146 2017-11-17
Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC
West China Hospital
Phase 1/2 Unknown
NCT00351039 2017-03-23
Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT00604461 2017-03-23
Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT00921310 2016-12-13
Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer
Washington University School of Medicine
Phase 1/2 Terminated
NCT00216203 2016-09-29
Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 1/2 Completed
NCT01666977 2016-06-03
Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer
Amgen
Phase 1/2 Completed